Gulf International Bank UK Ltd Has $7.83 Million Stock Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Gulf International Bank UK Ltd lowered its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 4.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 19,432 shares of the pharmaceutical company’s stock after selling 916 shares during the period. Gulf International Bank UK Ltd’s holdings in Vertex Pharmaceuticals were worth $7,825,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in VRTX. Arkadios Wealth Advisors acquired a new position in Vertex Pharmaceuticals during the third quarter worth $312,000. Traynor Capital Management Inc. acquired a new stake in Vertex Pharmaceuticals in the 3rd quarter valued at about $235,000. Integrated Advisors Network LLC increased its holdings in shares of Vertex Pharmaceuticals by 11.3% in the third quarter. Integrated Advisors Network LLC now owns 3,753 shares of the pharmaceutical company’s stock valued at $1,746,000 after purchasing an additional 381 shares in the last quarter. Fidelis Capital Partners LLC boosted its position in Vertex Pharmaceuticals by 5.5% in the 3rd quarter. Fidelis Capital Partners LLC now owns 5,465 shares of the pharmaceutical company’s stock valued at $2,569,000 after buying an additional 285 shares during the last quarter. Finally, Highview Capital Management LLC DE boosted its holdings in Vertex Pharmaceuticals by 2.4% in the third quarter. Highview Capital Management LLC DE now owns 5,669 shares of the pharmaceutical company’s stock valued at $2,637,000 after acquiring an additional 134 shares during the last quarter. 90.96% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Vertex Pharmaceuticals news, EVP Ourania Tatsis sold 310 shares of the company’s stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $459.83, for a total transaction of $142,547.30. Following the completion of the sale, the executive vice president now directly owns 64,021 shares in the company, valued at $29,438,776.43. This represents a 0.48 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.20% of the stock is owned by company insiders.

Vertex Pharmaceuticals Stock Performance

NASDAQ:VRTX opened at $479.10 on Thursday. The company has a current ratio of 2.69, a quick ratio of 2.35 and a debt-to-equity ratio of 0.01. The stock has a 50 day simple moving average of $437.18 and a 200 day simple moving average of $460.90. Vertex Pharmaceuticals Incorporated has a 1-year low of $377.85 and a 1-year high of $519.88. The stock has a market cap of $123.03 billion, a P/E ratio of -217.77, a PEG ratio of 2.11 and a beta of 0.41.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings data on Monday, February 10th. The pharmaceutical company reported $3.54 earnings per share for the quarter, missing the consensus estimate of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative return on equity of 2.02% and a negative net margin of 4.86%. Research analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on VRTX. Bank of America dropped their price target on shares of Vertex Pharmaceuticals from $545.00 to $522.00 and set a “buy” rating for the company in a research note on Thursday, December 19th. Truist Financial boosted their target price on Vertex Pharmaceuticals from $460.00 to $520.00 and gave the stock a “buy” rating in a research report on Tuesday, February 11th. StockNews.com lowered shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, February 19th. JPMorgan Chase & Co. cut their price objective on Vertex Pharmaceuticals from $503.00 to $500.00 and set an “overweight” rating on the stock in a report on Monday, December 23rd. Finally, Wells Fargo & Company cut shares of Vertex Pharmaceuticals from an “overweight” rating to an “equal weight” rating and set a $460.00 price objective on the stock. in a research report on Thursday, January 30th. Eleven research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $506.70.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.